Pembrolizumab
TianjinCIH20210096
Phase 3 mab active
Quick answer
Pembrolizumab for Esophageal Squamous Cell Carcinoma is a Phase 3 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Modality
- mab
- Status
- active